Orforglipron for adults with type 2 diabetes who fast during Ramadan
Tests orforglipron in adults with type 2 diabetes who fast for Ramadan.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Key facts
- Where
- Agra, Hyderabad, Kanpur, Kolkata, Mumbai, Mysore, Nashik, Nellore, and Visakhapatna, IndiaSee the 9 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who plan to fast during Ramadan and can join a study of the drug orforglipron.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with an HbA1c of at least 7.0% (53 mmol/mol) and less than 9.5% (91 mmol/mol) at screening. BMI of 25 kg/m2 or higher.
- Biomarker or test result
- HbA1c of at least 7.0% (53 mmol/mol) to less than 9.5% (91 mmol/mol) at screening.
Main reasons for not taking part
- Any diabetes other than type 2, such as type 1 or gestational diabetes
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- History of chronic or acute pancreatitis
- Gallbladder removed by surgery
- New York Heart Association class IV heart failure
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07613307, who can take part
Where in India
- Sarojini Naidu Medical CollegeAgra, IndiaContact: Prabhat Kumar Agrawal (principal investigator)Taking people
- Osmania General HospitalHyderabad, IndiaContact: Rakesh Kumar Sahay (principal investigator)Taking people
- Brij Medical Centre Pvt. Ltd.Kanpur, IndiaContact: Brij Mohan (principal investigator)Taking people
- Apollo Multispeciality Hospitals limitedKolkata, IndiaContact: Suvro Banerjee (principal investigator)Taking people
- KGN Diabetes and Endocrinology CentreMumbai, IndiaContact: Shehla Shaikh (principal investigator)Taking people
- Mysore Medical College and Research InstituteMysore, IndiaContact: Sumaiya Anjum (principal investigator)Taking people
- Supe Heart & Diabetes Hospital & Research CentreNashik, IndiaContact: Pravin Supe (principal investigator)Taking people
- Diabetes ClinicNellore, IndiaContact: Satyanarayana Murthy (principal investigator)Taking people
- Visakha Institute of Medical SciencesVisakhapatna, IndiaContact: Baratam Hari Kiran (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07613307
- Record updated
- 8 October 2026
- Original description
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.Read full original descriptionShow less
A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.
Inclusion: Have a clinical diagnosis of T2D based on the World Health Organization (WHO) classification or other locally applicable diagnostic standards; Have an HbA1c value of at least 7.0% (53 millimoles per mole (mmol/mol)) to less than 9.5% (91 mmol/mol) at screening; Intend to be compliant with the fast during the Ramadan period; Have had stable body weight self-reported change of 5 kilograms (kg) or lower during the 90 days prior to screening; Have body mass index (BMI) of 25 kilograms per meter square (kg/m2) or higher at screening.
Exclusion: Have a history of chronic or acute pancreatitis any time prior to screening; Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gestational diabetes, latent autoimmune diabetes, maturity-onset diabetes of the young, and medication-induced diabetes; Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years; Have a history of cholecystectomy (surgically removed gallbladder); Have New York Heart Association Functional Classification IV congestive heart-failure; Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxic or adrenal crises, in the opinion of the investigator.